Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: A retrospective drug utilisation study

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Black, Rachel J ^a,b,d   Joseph, Rebecca M ^a,c   Brown, Benjamin ^a   Movahedi, Mohammad ^a   Lunt, Mark ^a   Dixon, William G ^a,c,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d Centre for Inflammatory Disease Research (CIDR)   (Australia)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Drug utilisation; Glucocorticoids; Primary care; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; GLUCOCORTICOID; GOLD COMPLEX; HYDROCORTISONE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; ANTIRHEUMATIC AGENT;

AGE; AGING; ARTICLE; ASTHMA; ATOPIC DERMATITIS; AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG UTILIZATION; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSOMNIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYOPATHY; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PRESCRIPTION; PRIMARY MEDICAL CARE; PSYCHOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; STATISTICS; TREATMENT DURATION; UNITED KINGDOM; AGED; ARTHRITIS, RHEUMATOID; MIDDLE AGED; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG UTILIZATION; FEMALE; GENERAL PRACTITIONERS; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, PRIMARY CARE; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 84951822868     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0895-8     Document Type: Article

References (40)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions - a study in clinical physiology. Arch Intern Med. 1950;85:545-666.
2. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356.
3. Nassar K, Janani S, Roux C, Rachidi W, Etaouil N, Mkinsi O. Long-term systemic glucocorticoid therapy: patients' representations, prescribers' perceptions, and treatment adherence. Joint Bone Spine. 2014;81:64-8.
4. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-93.
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15-9.
6. National Institute of Health and Clinical Excellence. NICE clinical guideline 79. Rheumatoid arthritis. The management of rheumatoid arthritis in adults. London: NICE; 2009.
7. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128-33.
8. The Royal Australian College of General Practitioners (RACGP) clinical guidelines for the diagnosis and management of early rheumatoid arthritis. http://www.racgp.org.au/your-practice/guidelines/musculoskeletal/rheumatoidarthritis. Accessed November 2015.
9. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al. British Society for Rheumatology and British health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167-9.
10. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009;48:436-9.
11. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537-46.
12. Henkel G: Glucocorticoid use in rheumatoid arthritis management focus of ongoing debate. In: The Rheumatologist. vol. March 2015: ACR and ARHP; 2015.
13. Saag KG. Resolved: low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthr Care Res. 2001;45:468-71.
14. Conn DL. Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthr Care Res. 2001;45:462-7.
15. Clinical Practice Research Datalink. UK. http://www.cprd.com/home , Accessed August 2015.
16. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM. 1998;91:445-52.
17. García Rodríguez LA, Pérez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-25.
18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4-14.
19. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128-36.
20. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89-99.
21. Health and Social Care Information Centre-Read Codes. http://systems.hscic.gov.uk/data/uktc/readcodes. Accessed August 2015.
22. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum. 2008;59:1314-21.
23. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491-6.
24. Buttgereit F, Da Silva JAP, Boers M, Burmester G-R, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-22.
25. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142-6.
26. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998;37:930-6.
27. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:3371-80.
28. van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
29. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
30. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420-6.
31. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115-23.
32. Innala L, Berglin E, Moller B, Ljung L, Smedby T, Sodergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthr Res Ther. 2014;16:R94.
33. Villa-Blanco JI, Calvo-Alen J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26:739-50.
34. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-70.
35. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-71.
36. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21:S154-157.
37. Naumann L, Huscher D, Detert J, Spengler M, Burmester GR, Buttgereit F. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis. 2009;68:1934-6.
38. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol. 2009;27:807-13.
39. Nilsson AC, Christensen AF, Junker P, Lindegaard HM. Tumour necrosis factor-alpha inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011;58:A4257.
40. Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford). 2015;54:672-7.